Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients

Urology

Volumn 54, Issue 3, 1999, Pages 490-494

  Lee, Nancy ^b   Newhouse, Jeffrey H ^b   Olsson, Carl A ^b   Benson, Mitchell C ^b   Petrylak, Daniel P ^b   Schiff, Peter B ^b   Bagiella, Emilia ^b   Malyszko, Bozena ^b   Ennis, Ronald D ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TREATMENT INDICATION;

ADENOCARCINOMA; BONE NEOPLASMS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PELVIC BONES; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RADIOGRAPHY, ABDOMINAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032856247     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00150-8     Document Type: Article

References (14)

1. Landis SH, Murray T, Bolden, S, et al: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Pienta KJ, and Esper PS: Risk factors for prostate cancer. Ann Intern Med 118: 793-803, 1993.
3. Hricak H, Dooms GC, Jeffrey RB, et al: Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162: 331-336, 1987.
4. Partin AW, Kattan MW, Subong ENP, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 277: 1445-1451, 1997.
5. Oesterling JE, Moyad MA, Wright GL, et al: An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMX. Urology 46: 524-532, 1995.
6. Beahrs OH, Henson DE, Hutter RVP, et al: Manual for Staging of Cancer, 4th ed. Philadelphia, JB Lippincott, 1992, pp 177-182.
7. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60, 1993.
8. Levran Z, Gonzalez JA, Diokno AC, et al: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 75: 778-781, 1995.
9. Huncharek M, and Muscat J: Serum prostate-specific antigen as a predictor of staging abdominal pelvic computed tomography in newly diagnosed prostate cancer. Abdom Imaging 21: 364-367, 1996.
10. Morrison CC, Newhouse JH, Petrylak D, et al: Yield of CT and MRI for nodal metastases in recently diagnosed prostate cancer (abstract). Radiology 201(suppl): 188, 1996.
11. Rees MA, Resnick MI, and Oesterling JE: Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Urol Clin North Am 24: 379-388, 1997.
12. Gee WF, Holtgrewe L, Albertsen PC, et al: Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol 154: 207-208, 1995.
13. Barry MJ, Fowler FJ, Bin L, et al: A nationwide survey of practing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 158: 488-492, 1997.
14. Millikan R, and Logothetis C: Update of NCCN guidelines for treatment of prostate cancer. Oncolgy 11: 180-193, 1997.